| Literature DB >> 33615450 |
Yuqian Jiang1, Han Zhang1, Jose A Wippold2, Jyotsana Gupta3, Jing Dai1, Paul de Figueiredo3, Julian L Leibowitz3, Arum Han1,2.
Abstract
Heat treatment denatures viral proteins that comprise the virion, making the virus incapable of infecting a host. Coronavirus (CoV) virions contain single-stranded RNA genomes with a lipid envelope and four proteins, three of which are associated with the lipid envelope and thus are thought to be easily denatured by heat or surfactant-type chemicals. Prior studies have shown that a temperature as low as 75°C with a treatment duration of 15 min can effectively inactivate CoV. The degree of CoV heat inactivation greatly depends on the length of heat treatment time and the temperature applied. With the goal of finding whether sub-second heat exposure of CoV can sufficiently inactivate CoV, we designed and developed a simple fluidic system that can measure sub-second heat inactivation of CoV. The system is composed of a stainless-steel capillary immersed in a temperature-controlled oil bath followed by an ice bath, through which virus solution can flow at various speeds. Flowing virus solution at different speeds, along with temperature control and monitoring system, allows the virus to be exposed to the desired temperature and treatment durations with high accuracy. Using mouse hepatitis virus, a betacoronavirus, as a model CoV system, we identified that 71.8°C for 0.51 s exposure is sufficient to obtain >5 Log10 reduction in viral titer (starting titer: 5 × 107 PFU/ml), and that when exposed to 83.4°C for 1.03 s, the virus was completely inactivated (>6 Log10 reduction).Entities:
Keywords: COVID-19; SARS-CoV-2; coronavirus; heat inactivation of coronavirus; sub-second virus disinfection
Mesh:
Year: 2021 PMID: 33615450 PMCID: PMC8013827 DOI: 10.1002/bit.27720
Source DB: PubMed Journal: Biotechnol Bioeng ISSN: 0006-3592 Impact factor: 4.395
Figure 1Schematic illustration of the virus heat inactivation testing system [Color figure can be viewed at wileyonlinelibrary.com]
Figure 2The simulated temperature distribution of the entire heat inactivation testing system when using the oil bath to apply heat. The top color bar represents the axial cross‐sectional SS tubing, and traverse sectional views of positions i–iv are displayed in the right circles. (a) 125°C, 0.5 s exposure condition, along with the (b) corresponding traverse sectional views. (c) 170°C, 0.1 s exposure condition, along with the (d) corresponding traverse sectional view. Zone <1> pre‐oil bath; Zone <2> oil bath; Zone <3> ambient air; Zone <4> ice bath. The distance for simulation starts from 30 mm before the oil bath [Color figure can be viewed at wileyonlinelibrary.com]
Figure 3Effect of heat treatment on the infectivity of MHV. Remaining infectivity of MHV after different heat inactivation conditions (a) by oil bath set temperature and set exposure time; (b) by actual exposure temperature from real‐time measurement and actual exposure time based on simulation. Virus titers were averaged from three independent biological replicates (n = 3), and error bars indicate standard deviations. (c) Example images from the quantitative plaque assay that was used to determine posttreatment PFUs of the MHVs: (i) No plaque formation at high dilution but several plaques formed at low dilution indicates remaining infectivity of MHV; (ii) Examples of wells with too many plaques indicate large amount of infection‐capable MHVs, which require a further dilution to accurately conduct plaque count; (iii) Examples of plaque assay result after successful MHV heat inactivation (no plaque formation even at original “no diluted” sample solution, top red box), unsuccessful heat inactivation (or partial inactivation depending on its dilution; middle green box), and assays that need to be repeated at higher dilution for accurate plaque count (bottom purple box) [Color figure can be viewed at wileyonlinelibrary.com]
Summary of previously reported heat inactivation conditions with temperature ranging from room temperature to 120°C for heating duration from sub‐second to 1 h
| # | Temperature (°C) | Exposure duration | Remaining infectivity | Log10 reduction | Virus type | Other notes | References |
|---|---|---|---|---|---|---|---|
| 1 | 22–25 | 7 days | 1.5–2 | SARS CoV | RH 40%–50% | Chan et al. ( | |
| 2 | 22–25 | 28 days | >5 | SARS CoV | RH 40%–50% | Chan et al. ( | |
| 3 | 40 | 1 min | 0.16 | MHV‐2 | Saknimit et al. ( | ||
| 4 | 40 | 5 min | 0.33 | MHV‐2 | Saknimit et al. ( | ||
| 5 | 40 | 15 min | 0.34 | MHV‐2 | Saknimit et al. ( | ||
| 6 | 42 | 60 min | <1 | SARS‐CoV‐2 | Wang et al. ( | ||
| 7 | 56 | 1 min | 6.65 | SARS‐CoV‐2 | Chin et al. ( | ||
| 8 | 56 | 15 min | 4.92 | MERS‐CoV | Leclercq et al. ( | ||
| 9 | 56 | 15 min | 3–4 | SARS‐CoV‐2 | Wang et al. ( | ||
| 10 | 56 | 20 min | Incompletely inactivated | >5 | SARS‐CoV | Darnell et al. ( | |
| 11 | 56 | 30 min | Incompletely inactivated | >5 | SARS‐CoV‐2 | Pastorino et al. ( | |
| 12 | 56 | 30 min | ND | >4.51 | SARS‐CoV‐2 | Chin et al. ( | |
| 13 | 60 | 1 min | 2.60 | MHV‐2 | Saknimit et al. ( | ||
| 14 | 60 | 5 min | 3.55 | MHV‐2 | Saknimit et al. ( | ||
| 15 | 60 | 10 min | >6 | SARS‐CoV‐1 | Model prediction | Yap et al. ( | |
| 16 | 60 | 15 min | >4.51 | MHV‐2 | Saknimit et al. ( | ||
| 17 | 60 | 15 min | ND | >7 | SARS‐CoV‐2 | Wang et al. ( | |
| 18 | 60 | 30 min | >4.51 | MHV‐2 | Saknimit et al. ( | ||
| 19 | 60 | 60 min | Incompletely inactivated | >5 | SARS‐CoV‐2 | Pastorino et al. ( | |
| 20 | 60.2 | 0.20 s | >2 | MHV | This study | ||
| 21 | 65 | 30 s | 3.45 | MERS‐CoV | Leclercq et al. ( | ||
| 22 | 65 | 1 min | Incompletely inactivated | Data not shown | MERS‐CoV | Leclercq et al. ( | |
| 23 | 65 | 4 min | Incompletely inactivated | >5 | SARS‐CoV | Darnell et al. ( | |
| 24 | 65 | 15 min | ND | >5.59 | MERS‐CoV | Leclercq et al. ( | |
| 25 | 70 | 1 min | 5.34 | ~1.25 | SARS‐CoV‐2 | Chin et al. ( | |
| 26 | 70 | 5 min | ND | >4.5 | SARS‐CoV‐2 | Chin et al. ( | |
| 27 | 71.8 | 0.51 s | >5 | MHV | This study | ||
| 28 | 75 | 15 min | ND | >5 | SARS‐CoV | Darnell et al. ( | |
| 29 | 80 | <1 min | >6 | SARS‐CoV‐1 | Model prediction | Yap et al. ( | |
| 30 | 80 | 1 min | >4.51 | MHV‐2 | Saknimit et al. ( | ||
| 31 | 83.4 | 1.03 s | ND | >6 | MHV | This study | |
| 32 | 87.3 | 2.23 s | ND | >6 | MHV | This study | |
| 33 | 90 | 0.1 min | 6 | MERS‐CoV | Model prediction | Yap et al. ( | |
| 34 | 92 | 15 min | ND | >6 | SARS‐CoV‐2 | Pastorino et al. ( | |
| 35 | 110 | 0.1 min | 6 | SARS‐CoV‐1 | Model prediction | Darnell et al. ( | |
| 36 | 112 | 0.01 min | 6 | MERS‐CoV | Model prediction | Darnell et al. ( | |
| 37 | 120 | ~1 s | 6 | SARS‐CoV‐1 | Model prediction | Kratzel et al. ( |
Abbreviation: ND, not detectable.